Fitzpatrick Alexander A 4
4 · ARS Pharmaceuticals, Inc. · Filed May 22, 2025
Insider Transaction Report
Form 4
Fitzpatrick Alexander A
Chief Legal Officer
Transactions
- Sale
Common Stock
2025-05-20$14.10/sh−102,969$1,451,513→ 89,613 total - Exercise/Conversion
Common Stock
2025-05-20$5.58/sh+100,000$558,000→ 192,582 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-05-20−100,000→ 200,000 totalExercise: $5.58Exp: 2034-01-01→ Common Stock (100,000 underlying)
Footnotes (3)
- [F1]Includes 3,355 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024.
- [F2]The weighted average sale price for the transaction reported was $14.0966 and the range of prices were between $14.02 and $14.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]25% of the shares subject to the option vested on January 1, 2025, and the remaining shares will vest monthly thereafter over three years.